Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Queensland Health
Johnson and Johnson
Boehringer Ingelheim
Baxter
Mallinckrodt
Chubb
Fish and Richardson
Citi

Generated: May 22, 2018

DrugPatentWatch Database Preview

AMINOSYN 8.5% W/ ELECTROLYTES Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

When do Aminosyn 8.5% W/ Electrolytes patents expire, and when can generic versions of Aminosyn 8.5% W/ Electrolytes launch?

Aminosyn 8.5% W/ Electrolytes is a drug marketed by Icu Medical Inc and is included in one NDA.

The generic ingredient in AMINOSYN 8.5% W/ ELECTROLYTES is amino acids; magnesium chloride; potassium phosphate, dibasic; sodium chloride. There are three hundred and forty-five drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the amino acids; magnesium chloride; potassium phosphate, dibasic; sodium chloride profile page.

US Patents and Regulatory Information for AMINOSYN 8.5% W/ ELECTROLYTES

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Icu Medical Inc AMINOSYN 8.5% W/ ELECTROLYTES amino acids; magnesium chloride; potassium phosphate, dibasic; sodium chloride INJECTABLE;INJECTION 017673-005 Approved Prior to Jan 1, 1982 RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Argus Health
Merck
Deloitte
Baxter
Cantor Fitzgerald
Chinese Patent Office
AstraZeneca
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.